Jiang Ping, Ji Siqi, Su Dan, Zhao Yu, Goncalves Viriania Berta Esperanca, Xu Guifang, Zhang Mingming
Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu, China.
Authors contributed equally.
Microbiome Res Rep. 2024 Sep 5;3(4):47. doi: 10.20517/mrr.2024.12. eCollection 2024.
Intestinal homeostasis is essential for maintaining human health, and its dysfunction is related to the onset and progression of various diseases, including immune and metabolic disorders, and even tumorigenesis. Intestinal microbiota plays a critical role in intestinal homeostasis, with () emerging as a key commensal bacterium utilizing mucin as its sole carbon and nitrogen source. has been recognized in both experimental and clinical studies for its beneficial role in managing intestinal inflammation, tumors, functional gastrointestinal disorders, and secondary conditions such as liver and metabolic diseases. This review provides a comprehensive overview of the research history and current understanding of , its association with various intestinal-related diseases, and the potential mechanisms behind its effects. This paper also explores the possibilities of leveraging the probiotic enzyme such as the active ingredients of for the innovative clinical treatment of intestinal-related diseases.
肠道稳态对于维持人类健康至关重要,其功能失调与多种疾病的发生和发展相关,包括免疫和代谢紊乱,甚至肿瘤发生。肠道微生物群在肠道稳态中起关键作用,其中()作为一种关键的共生细菌出现,它利用粘蛋白作为其唯一的碳源和氮源。在实验和临床研究中,()因其在管理肠道炎症、肿瘤、功能性胃肠疾病以及肝脏和代谢疾病等继发病症方面的有益作用而得到认可。本综述全面概述了()的研究历史和当前认识、其与各种肠道相关疾病的关联以及其作用背后的潜在机制。本文还探讨了利用益生菌酶如()的活性成分对肠道相关疾病进行创新临床治疗的可能性。